Renal Cancer - Results from #1440

Disparity in public funding of systemic therapy for metastatic renal cell carcinoma within Canada. June 17, 2022

The Impact of Venous Thromboembolism on Mortality and Morbidity During Nephrectomy for Renal Mass. June 17, 2022

Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study. June 16, 2022

Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients. June 16, 2022

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. June 15, 2022

Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness. June 15, 2022

A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System (CKCis). June 14, 2022

A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. June 14, 2022

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. June 13, 2022

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. June 13, 2022

Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. June 10, 2022

Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma. June 10, 2022

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. June 9, 2022

Does size matter? Comparing robotic versus open radical nephrectomy for very large renal masses. June 9, 2022

Pathologic fracture in metastatic kidney cancer: Identifying widening disparities and opportunity for quality improvement. June 8, 2022

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States. June 8, 2022

MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets. June 7, 2022

Benefit and Harm of Active Surveillance for Biopsy-proven Renal Oncocytoma: A Systematic Review and Pooled Analysis. June 7, 2022

Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma. June 6, 2022

Development of a Phagocytosis-Dependent Gene Signature to Predict Prognosis and Response to Checkpoint Inhibition in Clear-Cell Renal Cell Carcinoma. June 6, 2022

Page 73 of 456